FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, [	D.C. 20549
---------------	------------

STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Or Yat Sun				E	2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC ENTA ]						(Ch	eck all applic	cable)	Person(s) to Iss 10% Ov Other (s	vner	
(Last) C/O ENA	•	irst) ARMACEUTIC <i>A</i>	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/22/2023							X Officer (give title below)  Sr. VP, R&D & CSO			
500 ARSENAL STREET					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) WATER	TOWN M	1A	02472											led by More	Reporting Perso	
(City) (State) (Zip)					Rı	Rule 10b5-1(c) Transaction Indication										
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								d to								
		Tab	le I - Non	-Deriv	vativ	e Se	curities	Ac	quired, D	isposed	of, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Transaction Disposed Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		5. Amou Securitie Beneficia Owned F Reported	s Fally (I	orm: Direct	7. Nature of Indirect Beneficial Ownership			
							Code V	Amount	(A) o	r Price	Transact (Instr. 3	ion(s)		(Instr. 4)		
		-	Fable II - I						uired, Dis , options,				Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day)	oate,	Code (Instr		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$8.99	11/22/2023			A		86,000		(1)	11/22/2033	Common Stock	86,000	\$0.00	86,000	D	

## **Explanation of Responses:**

1. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

/s/ Nathaniel S. Gardiner as attorney-in-fact

11/22/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.